DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: Results from genotyping study on 75 gastric carcinoma and colon carcinoma patients

Medical Oncology

Volumn 24, Issue 2, 2007, Pages 251-258

  Zhang, Hong ^a   Li, You Ming ^a   Zhang, Hao ^b   Jin, Xi ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UCB PHARMA   (Belgium)

Author keywords

Chemotherapy; DPYD; Gastrointestinal carcinoma; Gene polyporphism; Side effect

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; OXALIPLATIN; ANTINEOPLASTIC ANTIMETABOLITE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; COLON CARCINOMA; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG BLOOD LEVEL; ENZYME ACTIVITY; FEMALE; GENE LOCUS; GENE MUTATION; GENOTYPE; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; PRIORITY JOURNAL; STOMACH CARCINOMA; BLOOD; CARCINOMA; COLORECTAL TUMOR; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; STOMACH TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA; COLORECTAL NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC; STOMACH NEOPLASMS;

EID: 36249014288     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02698048     Document Type: Article

References (24)

1. Ciccolini J, et al. Toxic death-case after capecitabine+ oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine dehydro- genase deficiency. Cancer Chemother Pharmacol 2006; 58: 272-275.
2. Lazar A, et al. Multiple organ fail due to 5-fluorouracil chemotherapy in a patient with a rare dihydropyrimidine dehydrogenase gene variant. Onkologie 2004; 27: 559-562.
3. van Kuilenburg AB, De Abreu RA, van Gennip AH. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency. Ann Clin Biochem 2003; 40: 41-45.
4. Ciccolini J, et al. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPYD) activity. J Clin Pharm Ther 2004 29: 307-315.
5. Ritschel, W.A. Handbook of Basic Pharmacokinetics, 2nd ed. Drug Intelligence Publications, 1980, pp 413-426. http://www.boomer.org/c/p3/c02/ c0204.html
6. Toffoli G, Cecchin E. Phamacogenetics of stomach cancer. Pharmacogenomics 2004; 5: 627-641.
7. Nagasubramanian R, Innocenti F, Ratain MJ. Pharmacogenetics in cancer treatment. Annu Rev Med 2003; 54: 437-452.
8. Van Kuilenburg AB, et al. Genotype and phentype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet 1999: 104: 1-9.
9. McLeod HL, et al. Nomenclature for human DPYD alleles. Pharmacogenetics 1998; 8: 455-459.
10. Johnson MR, Diasio RB. Importance of dihydropyrimidine dehydrogenase (DPYD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv Enzyme Regul 2001; 41: 151-157.
11. Meinsma R, et al. Human polymorphism in drug metabolism mutation in the dihydropyrimidine dehydrogenase gene result in exon skipping and thymine uracilurea. DNA Cell Biol 1995; 14: 1-6.
12. Van Kuilenburg AB, et al. High prevalence of the IVS14+1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 2002; 12: 555-558.
13. Van Kuilenburg AB, et al. Increase risk of grade IV neutropenia after administration of 5-fluorouracial due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1G>A mutation. Int J Cancer 2002; 101: 253-258.
14. Hasegawa T, et al. Sequence analysis of the 5′-flanking regions of human dihydropyrimidine dehydrogenase gene: identification of a new polymorphism related with effects of 5-fluorouracil. Neuleosides Nucleotides Nucleic Acids 2005; 24: 233-242.
15. Mattison LK, Johnson MR, Diasio RB. A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA: conservation of functional domains and relevances to genetic polymorphisms. Pharmacogenetics 2002; 12: 133-144.
16. Hsiao HH, et al. Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population. Cancer Chemother Pharmacol 2004; 53: 445-451.
17. Wei X, et al. Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics 1998; 51: 391-400.
18. Ahluwalia R, et al. Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase. Clin Chem 2003; 49: 1161-1164.
19. Van Kuilenburg AB, et al. Lethal outcorne of a patent with a complete dihydropyrimidine dehydrogenase (DPYD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1 G>A mutation causing DPYD deficiency. Clin Cancer Res 2001; 7: 1149-1153.
20. Raida M, et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPYD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compare with controls. Clin Cancer Res 2001; 7: 2832-2839.
21. Van Kuilenburg AB, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPYD) deficiency in patients with severe 5-fluorouracil associated toxicity: identification of new mutations in the DPYD gene. Clin Cancer Res 2000; 6: 4705-4712.
22. Di Paolo A, et al. Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dyhydrogenase activity in cancer patients. Ann Oncol 2001; 12: 1301-1306.
23. Lee W, et al. Cancer pharmacogenomocs: powerful tools in cancer chemotherapy and drug development. Oncologist 2005; 10: 104-111.
24. Kleyn PW, Vesell ES. Genetics variation as a guide to drug development. Science 1998; 281: 1820-1821.